Special Access Program for drugs: Guidance document for industry and practitioners

This guidance document explains the regulatory information requirements and conditions for practitioners and manufacturers when drugs are requested through the Special Access Program (SAP). It explains SAP's mandate, intent and scope, and outlines the responsibilities of practitioners and manufacturers.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 21:34 (TU)
Créé le avril 17, 2026, 21:34 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2022-04-05 00:00:00
open_canada_keywords {"fr": ["programme d'accès spécial", "SAP", "médicaments", "document d'orientation", "industrie", "praticiens"], "en": ["special access program", "SAP", "drugs", "guidance document", "industry", "practitioners"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Programme d’accès spécial aux médicaments : Ligne directrice à l’intention de l’industrie et des praticiens
update_frequency as_needed